Wolverine legal status: Is pharmacy use allowed?
BPC-157 and TB-500 have no clear pharmacy answer. A July 2026 group advised FDA, but FDA has not ruled.
Wolverine legal status has no clear pharmacy answer
Is the BPC-157 and TB-500 pair allowed? FDA records don't give a simple yes or no. On July 23–24, 2026, FDA staff asked a pharmacy group to weigh both ingredients [3]. The question was whether both raw drugs belonged on the pharmacy list. FDA staff said neither one belonged. By September 2026, FDA had not posted how the group voted. The group only advises FDA. Its meeting was not a final ruling [3].
FDA’s list gives the clearest dates. Both substances entered a safety warning group called Category 2 on September 29, 2023. The group covers raw drug ingredients that may pose a serious risk. On April 22, 2026, FDA marked each request withdrawn [2]. FDA still showed the reasons for its concern.
Category 1 meant FDA would usually wait to act while it reviewed an ingredient. Category 2 never had that pause. FDA has said it may act when a pharmacy makes a drug from a Category 2 ingredient [1]. FDA hasn't said what a withdrawn request permits now. Leaving Category 2 does not give a pharmacy permission. This page gives facts, not medical or legal advice. FDA has not given the clear yes you may want.
Both requests left Category 2 before July 2026
What changed for the two Wolverine parts? The people who asked FDA to review each ingredient pulled both requests. The BPC-157 record does not say why. FDA staff also said neither raw ingredient belonged on the list local pharmacies may use. As of September 2026, FDA had not posted votes from the July 2026 meeting [2][3].
FDA reviewed two chemical forms of BPC-157. Its page does not show that either form is safer or works better for a patient. FDA put BPC-157 in the warning group called Category 2 on September 29, 2023 [2]. FDA cited a possible immune-system reaction with some ways of giving it. FDA did not report finding bad vials. It warned that the main ingredient might be wrong or have stray protein pieces. BPC-157 isn't an FDA-approved drug [2].
FDA described the short piece as seven amino acids from the larger thymosin beta-4 protein. TB-500 also entered Category 2 on September 29, 2023 [2]. FDA cited a possible immune-system reaction and missing safety facts. Its page again says that TB-500 is a seven-amino-acid part of thymosin beta-4 [2]. TB-500 isn't an FDA-approved drug [2].
The July 23–24, 2026 meeting list named both ingredients [3]. The group weighed whether pharmacies could use them as raw ingredients. A meeting is just one step. It isn't a final choice [1]. “Withdrawn” means the request ended. It does not mean allowed.
A prescription does not make every ingredient lawful
Compounding in the U.S. is governed by two sections of the Federal Food, Drug, and Cosmetic Act. Section 503A covers traditional, patient-specific compounding by state-licensed pharmacies and physicians, generally pursuant to a valid prescription for an individual patient. Section 503B covers FDA-registered outsourcing facilities that compound larger batches under stricter oversight [1]. A compounder may use a bulk drug substance only if it has an applicable USP/NF monograph, is a component of an FDA-approved drug, or appears on the relevant FDA bulks list; substances not yet listed are evaluated by FDA through a public nomination process informed by PCAC [1].
The lawful access pathway runs in order. A patient is evaluated by an appropriately licensed prescriber — in person or via a compliant telehealth encounter — who determines whether a compounded preparation is clinically appropriate [4]. If appropriate and lawful, the prescriber issues a valid, patient-specific prescription. The prescription is then dispensed by a state-licensed 503A compounding pharmacy, or for office and batch use sourced from an FDA-registered 503B outsourcing facility [4]. Telehealth is one front-end channel for the prescriber-evaluation step; it does not expand which substances may be compounded and does not remove the need for a legitimate clinical evaluation and a valid prescription [4].
Promise Peptides (mypromise.com) clinicians may prescribe Wolverine (research blend) only after a licensed clinical evaluation; that patient-specific prescribing step does not settle the separate question of whether a pharmacy may legally compound the ingredients.
The ingredient-eligibility caveat is the binding one here. FDA's published framework ties use of bulk ingredients to the statutory 503A/503B conditions, but FDA has not explained how a pharmacy should treat an ingredient after its nominator takes the request back [4]. On FDA's April 22, 2026 page, BPC-157 and TB-500 appear with withdrawn nominations rather than in Category 2, while the agency leaves its safety rationales in place and gives no specific direction to pharmacies about that listing [2].
FDA records still do not tell a pharmacy yes or no
What do the FDA records answer? They show dates, pulled requests, and safety concerns. The July 2026 group only advised FDA. No votes or final rule are posted. A prescription does not make an ingredient lawful by itself.
Current FDA rules do not clearly allow Wolverine (BPC-157 + TB-500)
Is Wolverine (BPC-157 + TB-500) legal under current FDA rules? Neither substance has FDA drug approval. FDA hasn't approved any use for Wolverine [2]. Both requests are now marked withdrawn, not Category 2. That warning group covered ingredients that may pose serious safety risks. FDA’s page still shows the safety concerns [1][2]. Pulling a request does not give a pharmacy permission. The World Anti-Doping Agency sets rules for tested sports and bars both [15]. Lawful access still depends on the doctor, prescription, pharmacy, and ingredient [4]. Every part must meet the law.
Local pharmacies still lack a rule for making BPC-157
A compounding pharmacy mixes a drug for one patient. FDA placed BPC-157 in the safety warning group called Category 2 on September 29, 2023 [1][2]. Its April 22, 2026 page marks the request withdrawn. FDA hasn't told local pharmacies what that change lets them do. BPC-157 reached the July 23–24, 2026 meeting. FDA staff said it did not belong on the raw-drug list. No vote record has been posted [3]. A pulled request isn't approval.
FDA has not told local pharmacies to use Wolverine ingredients
What rule applies to a local pharmacy now? The federal rule called 503A covers a pharmacy that mixes a drug for one patient. FDA’s April 22, 2026 page says both people who filed requests withdrew them [1][2]. That moved both ingredients out of Category 2, the warning group for possible serious safety risks. FDA kept its concerns and gave no clear pharmacy rule. Neither substance is on the raw-drug list for those pharmacies. Both reached the July 23–24, 2026 meeting. FDA still hasn't published the vote record [3]. The practical answer remains uncertain.